BioSpace News Archive

Aya Healthcare, the company transforming healthcare staffing and workforce solutions across the United States, was included on Inc. Magazine’s annual Inc. 5000 list — a ranking of the nation’s fastest-growing private companies.

AstraZeneca and Merck’s LYNPARZA when added to standard-of-care bevacizumab significantly increased the time women lived without disease progression or death

Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell and small molecule technologies, reported its financial results for the second quarter ended June 30, 2019.

Paragon Private Health, with offices in New York, NY and Richmond, VA has been named to the prestigious Inc. 5000 list of the fastest growing private companies in America.

ESSA Pharma Inc. (“ESSA”, or the “Company”) (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal third quarter ended June 30, 2019

Holon Solutions, healthcare’s leading data liberator, announced today that Great Lakes Health Connect (GLHC), one of the largest health information exchanges (HIEs) in the country, has surpassed access to more than 1 million closed-loop referrals statewide since Fall 2017 using Holon’s CollaborNet® Referrals application.

Inc. magazine today revealed that Competitive Health, Inc. is No. 3072 on its annual Inc. 5000 list, the most prestigious ranking of the nation’s fastest-growing private companies

Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today reported financial results for the second quarter of 2019.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced the appointment of Orly Mishan as chief business officer

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the Company has treated the first patients in its pivotal cellulite trial.